

Abstract

The problem of replication competent adenovirus in virus production is solved in
that we have developed packaging cells that have no overlapping sequences with a new
basic vector and thus are suited for safe large scale production of recombinant adenoviruses.

One of the additional problems associated with the use of recombinant adenovirus vectors
is the host-defense reaction against treatment with adenovirus. Another aspect of the
invention involves screening recombinant adenovirus vector lots, especially those intended
for clinical use, for the presence of adenovirus E1 sequences, as this will reveal
replication competent adenovirus, as well as revertant E1 adenoviruses. It is also an aspect
of the present invention to molecularly characterize the revertants that are generated in the
newer helper/vector combinations.

15 N:\2578\3935\3935_pat.wpd 7/19/99